DPC Stock Soars 67% In 3Q On Strength Of Immulite Sales, IVD Market Growth
This article was originally published in The Gray Sheet
Executive Summary
Solid sales of Diagnostic Products Corp.' s reagents for the Immulite immunoassay platform, combined with revived growth in the immunoassay segment of the in vitro diagnostic market triggered a 67.2% gain in the company's stock price during the third quarter of 2000.
You may also be interested in...
Abbott's AFP, CA 125 Cancer Tests Unaffected By Consent Decree
Abbott Laboratories' AFP and CA 125 diagnostic cancer tests are among the diagnostic products deemed "medically necessary" by FDA and will continue to be made available under the company's Nov. 2 consent decree with the agency.
DPC Places 10-15 Immulite 2000 Units In U.S. Since Launch In Early March
Diagnostic Products Corp. has placed 10-15 Immulite 2000 immunodiagnostic analyzers in the U.S. and over 100 worldwide, the company says.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.